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Abstract
Inherited mitochondrial DNA (mtDNA) mutations have emerged as a common cause of
human disease, with mutations occurring multiple times in the world population. The clinical
presentation of three pathogenic mtDNA mutations is strongly associated with a background
mtDNA haplogroup, but it is not clear whether this is limited to a handful of examples or is a
more general phenomenon. To address this, we determined the characteristics of 30,506
mtDNA sequences sampled globally. After performing several quality control steps, we
ascribed an established pathogenicity score to the major alleles for each sequence. The
mean pathogenicity score for known disease-causing mutations was significantly different
between mtDNA macro-haplogroups. Several mutations were observed across all hap-
logroup backgrounds, whereas others were only observed on specific clades. In some
instances this reflected a founder effect, but in others, the mutation recurred but only within
the same phylogenetic cluster. Sequence diversity estimates showed that disease-causing
mutations were more frequent on young sequences, and genomes with two or more dis-
ease-causing mutations were more common than expected by chance. These findings
implicate the mtDNA background more generally in recurrent mutation events that have
been purified through natural selection in older populations. This provides an explanation for
the low frequency of mtDNA disease reported in specific ethnic groups.
Author summary
MtDNA mutations are a major cause of genetic disease. Many of these variants have
recurred several times in different populations and on diverse haplogroup backgrounds,
but the clinical presentation of mutations causing Leber Hereditary Optic Neuropathy
(LHON: m.14484T>C, m.3460G>A, m.11778G>A) are strongly associated with a
specific mtDNA haplogroup. This raises the possibility that many pathogenic mtDNA
mutations are subject to the same effects. Here, our analysis of 30,506 human mtDNA
sequences shows that the association between disease-causing mtDNA mutations and
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background mtDNA haplogroups is not only restricted to three disease-causing mtDNA
mutations known to cause LHON. The frequent recurrence of the same mutations on a
population clade, and the reduced frequency of European mtDNAs harboring two or
more diseases-causing mutations, suggest that the population mtDNA background influ-
ences the risk of developing mtDNA mutations. Our analysis also shows that disease-caus-
ing mtDNA mutations also occur more frequently on younger mtDNAs. This implies
that, once formed, the mutations are selected against. These findings indicate that the clin-
ical interpretation of mtDNA variants should be performed within an ethnogeographic
context.
Introduction
Human mitochondrial DNA (mtDNA) is exclusively maternally inherited and undergoes neg-
ligible recombination at the population level. As humans emerged from Africa and populated
the globe, different sub-populations acquired single nucleotide variants (SNVs) that define
geographically-restricted mtDNA ‘haplogroups’[1]. Some rare genetic variants have emerged
as a common cause of inherited metabolic disease, affecting 1 in 10,000 of the population[2].
Many of these variants have recurred several times in different populations and on diverse
haplogroup backgrounds, but the clinical presentation of mutations causing Leber Hereditary
Optic Neuropathy (LHON: m.14484T>C, m.3460G>A, m.11778G>A) are strongly associated
with a specific mtDNA haplogroup[3, 4]. This raises the possibility that many (but not all[5])
pathogenic mtDNA mutations are subject to the same effects. This has not been systematically
studied to date, in large part because of the limited number of sequences available for analysis.
Results
Data description and quality control
30,506 mtDNA sequences were downloaded from GenBank (S1 Table and S2 Table). These
included 3,852 sequences from macro-haplogroups L, 6,202 from M and 20,452 from N. In
17,815 of the 30,506 mtDNA sequences it was possible to identify all known appropriate hap-
logroup markers down to the sub-haplogroup level [6, 7] (http://www.phylotree.org/tree/
index.htm) (referred to as ‘sub-haplogroup tagged’ S1 Table). Next we compared the fre-
quency of the variants to the remaining 12,691 sequences (referred to as non-sub-haplogroup
tagged), stratifying for each macro-haplogroup (2,710 sequences from L, 2,619 from M, and
7,362 from N; S1 Table). The allele frequencies were strongly correlated between the two
groups (R2 = 0.842, p-value< 2.2e-16 for macro-haplogroup L; R2 = 0.968, p-value< 2.2e-16
for macro-haplogroup M; R2 = 0.988, p-value< 2.2e-16 for macro-haplogroup N, Person’s
correlation test; Fig 1A, S1A Fig).
Next we compared the allele frequencies in the 17,790 European haplogroup N(R) se-
quences to an independent sample of 9935 population controls from the Wellcome Trust
Case Control Consortium [8]. Allele frequencies from the 59 mtDNA variants present in
both datasets were highly correlated (R2 = 0.953, p-value< 2.2e-16, Person’s correlation test;
Fig 1B). We then compared 30,506 mtDNA sequences with 1,370 mtDNA sequences from
1000 Genome Project (see Methods), which includes mtDNA sequences from across the world
(462 from macro-haplogroup L, 271 from M, and 637 from N). The allele frequencies of
the mtDNA variants were highly correlated between two datasets for each macro-haplogroup
(R2 = 0.941, p-value< 2.2e-16 for macro-haplogroup L; R2 = 0.989, p-value< 2.2e-16 for
macro-haplogroup M; R2 = 0.985, p-value< 2.2e-16 for macro-haplogroup N; Pearson’s
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correlation test; Fig 1C, S2 Fig, S3 Fig). Further evidence of quality control came from an
independent comparison of the GenBank dataset to 1,125 published global human mtDNA
sequences from the literature [9], where the ratios of non-synonymous variants (NS) and syn-
onymous variants (SS) within major haplogroups were no different (p-value> 0.05, Fisher
test; Fig 1D). Finally the allele frequencies of common disease-causing mutations were no dif-
ferent to previously published values derived from a healthy population birth cohort in Euro-
peans (i.e. an established ‘population carrier frequency’ for these mutations, p-value> 0.05,
Fig 1. mtDNA sequence quality control. (A) Correlation of allele frequencies of the variants between 17,815 sub-haplogroup tagged mtDNA sequences
and the remaining 12,691 non sub-haplogroup tagged mtDNA sequences. (B) Correlation of 59 mtDNA variant frequencies between 9,935 independent
population controls from the Wellcome Trust Case Control Consortium and this study. (C) Correlation of allele frequencies of the variants between 1,370
mtDNA sequences from 1000 Genome Project (1kg) and 30,506 GenBank NCBI mtDNA sequences. (D) Ratio of non-synonymous (NS) to synonymous (S)
mtDNA variants in 30,506 mtDNA sequences compared to an independent published dataset [9], the numbers of NS and S are shown in bar chart at the
bottom. (E) Allele frequencies of ten common disease-causing mutations. There was no difference when compared to previously published values
determined through a population-based study in sequential healthy live-births in Europeans[10].
https://doi.org/10.1371/journal.pgen.1007126.g001
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Fisher test; Fig 1E)[10], providing further evidence that our dataset is not significantly
enriched with sequences derived from patients with inherited mtDNA diseases in the Euro-
pean population. A similar comparison was not currently possible for African and Asian
mtDNAs. However, we saw no relationship the pathogenicity score of specific alleles and the
difference in allele frequency and sub-haplogroup tagged vs. non-sub-haplogroup tagged
mtDNAs in our data set (See Methods for an explanation of pathogenicity scores, S1B Fig).
When taken together, these analysis (Fig 1A–1E), indicate that the 30,506 GenBank sequences
are a representative sample of the background populations and not significantly enriched for
rare population variants or pathogenic mutations identified through patients presenting with
mitochondrial diseases.
Determining the disease caused mutations
The 30,506 mtDNA sequences were predicted to cause 10,166 unique single amino acid substitu-
tions (L = 3,732, M = 4,887, N = 8,427, Fig 2A). There was no difference in the frequency distribu-
tion for mtDNA variants between the macro-haplogroups (p-value = 1, ANOVA test; Fig 2B).
Next we determined which variants were likely to be pathogenic. Ninety of the 202 proposed path-
ogenic mtDNA variants listed on the ClinVar database[11] were found in the 30,506 mtDNA
sequences studied here (S3 Table). Incorporating published and on-line evidence of pathogenicity
(see Methods), the number of likely pathogenic mutations reduced from 90 to 57(S4 Table).
Pathogenicity of variants in macro-haplogroups L, M and N
We initially focused on the pathogenicity of all variants within protein-encoding genes. 2,709
variants were present in 30,506 sequences, including 34 disease-causing mutations (S4 Table).
As expected, variants with a higher pathogenicity score were less frequent in the population,
and disease-causing mutations with a higher pathogenicity score were less frequent in the pop-
ulation (Fig 2C). Likewise, as expected, the probability distribution of pathogenicity scores for
disease-causing mutations was significantly greater than the overall distribution of pathogenic-
ity scores in the entire population (mean = 0.59 for disease-causing mutations, mean = 0.37
for all possible variants; two-sample t-test, p-value< 2.2e-16, Fig 2C). However, we were sur-
prised to see that disease-causing mutations on the macro-haplogroup N and M backgrounds
had significantly higher pathogenicity score than those occurring on the macro-haplogroup L
background (mean = 0.47 for L group, mean = 0.62 for M group, mean = 0.59 for N group; L
versus M: p-value = 1.959e-11, L versus N: p-value = 7.992e-08, M versus N: p-value = 8.967e-
07, two-sample t test, Fig 2D). These differences could not be accounted for by the frequency
of specific mutations, which did not follow the same trend (S4 Fig). 83(2.2%) mtDNA se-
quences carried at least one disease-causing mutation in L group, 481 (7.8%) in M group and
1,057 (5.2%) in N group. Group M sequences had a higher proportion of sequences carrying
disease-causing mutations 481 (7.8%), followed by group N sequences 1,057 (5.2%), with the
lowest in group L 83 (2.2%) (L versus M: p-value = 1.39e-36, L versus N: p-value = 9.49e-19, M
versus N: p-value = 1.43e-13, Fisher test, Fig 2E).
Based on the overall frequency of disease causing mutations, we estimated the likelihood of
a second mutation occurring by chance on the same genome (Fig 2F). For macro-haplogroups
L and M, the observed frequency of mtDNAs with two of more disease-causing mutations was
no different to the chance co-occurrence. However, for macro-haplogroup N sequences, the
number of mtDNA sequences harboring two of more disease-causing mutations was 6-fold
lower than expected by chance (p-value = 5.96e-09, Fisher test; Fig 2F). These observations
implicate the mtDNA sequence background in the likelihood of acquiring or retaining a dis-
ease-causing mutation.
Background sequence characteristics influence mtDNA mutations
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We then determined the frequency of the 57 disease-causing mutations on the ‘major’ hap-
logroups. Twenty-five (43.9%) of the 57 diseases-causing mutations were present on more
than one macro-haplogroup, and 34 (59.6%) were present on more than one major hap-
logroup (Fig 3A, S5 Fig), indicating recurrent mutation events. 23 (40.4%) of the pathogenic
mutations were only found on one haplogroup. Of these, m.4136A>G, m.4317A>G,
m.7444G>A, m.11696G>A. and m.13637A>G were recurrent mutations based on analysis of
the entire mtDNA sequence. This suggests that specific mtDNA mutations recur on specific
mtDNA haplogroups, implying that the background haplogroup predisposes to the original
mutation event, or the subsequent fixation of the allele on a particular maternal lineage. On
the other hand, m.5631G>A (L), m.10663T>C (L), m.8313G>A (M), m.12770A>G (M), and
m.3890G>A (N) were only seen on one clade, consistent with a single founder event. This
raises the possibility that these several ‘disease-causing’ mutations are actually rare sub-hap-
logroup markers and not directly pathogenic (eg m.4295A>G, m.6489C>A). Overall, we
found statistical evidence of haplogroup clustering for 10 (29.4%) of the 34 recurrent disease-
causing mtDNA mutations after correcting for the sample size within each comparison (p-
value < 0.01, Fisher test; Fig 3B).
Mutational signature
We then determined the relative frequency of mutations within all 96 possible flanking nucleo-
tide triplets[12]. Overall, across all macro-haplogroups we saw a greater prominence of C>T/
A>G and T>C/A>G substitutions for all variants (p< 2.2e-16, Fisher test; Fig 4A–4C), and
for disease causing mutations (p< 2.2e-16, Fisher test; Fig 4D–4F). In order to confirm the
prominence of C>T and T>C mutations observed were not due to the selection of the rCRS
[13] as the “reference” by which the mutations are classified, we realigned 30,506 mtDNA
sequences to Reconstructed Sapiens Reference Sequence (RSRS) [14]. We observed similar
patterns, with T>C and C>T substitutions frequently observed (S6 Fig), suggesting the pro-
files of mutational signatures were not driven by the alignment process and are independent of
the reference sequence used in the analysis.
We also observed that the higher mutability of CpG dinucleotides in disease-causing muta-
tions when compared to all variants (CpG%, p-value = 0.00017, Fisher exact test; S7 Fig and
S5 Table). Although the methylation of mtDNA appears to be rare in somatic tissues [15],
nuclear genome methylation changes substantially during embryonic and germ-line develop-
ment [16], raising the possibility that methylation of mtDNA CpGs during early development
contributes to the origin of de novo mtDNA mutations [17]. Intriguingly, macro-haplogroup
M had highest CpG% for all variants (19.93%; L versus M, p-value< 2.2e-16 and M versus N
p-value< 2.2e-16 Fisher exact test) and defined diseases-causing mutations (21.21%; L versus
M, p-value = 0.00049; and M versus N, p-value = 1.06e-06). By contrast, macro-haplogroup L
Fig 2. The distribution of variant frequency and assessing the pathogenicity score in 30,506 mtDNA sequences. (A) Circos plot summarizing
all of the genetic data in 30,506 mtDNA sequences. From outside the circle to inside: (1) mtDNA position, (2) mtDNA genes, (3) mtDNA Complex, (4)
frequency of all variants in 30,506 mitochondrial sequences(range 0 to 98.70%), (5) frequency of diseases-causing mutations in 30,506 mitochondrial
sequences(range 0 to 0.89%), (6) frequency of all variants in L group(range 0 to 99.45%), (7) frequency of diseases-causing mutations in L group
(range 0 to 0.65%), (8) frequency of all variants in M group(range 0 to 99.60%), (9) frequency of diseases-causing mutations in M group(range 0 to
3.11%), (10) frequency of all variants in N group(range 0 to 98.60%), (11) frequency of diseases-causing mutations in N(range 0 to 1.26%), Color
code for circles (4)–(11): Red—frequency of diseases-causing mutations, blue—frequency of all variants. (B) The distribution of frequency of variants
in each macro-haplogroup. MtDNA variants in were ordered based on frequency from high to low. The right-hand panel highlights the variants with
frequency above 0.5% in each group. (C) Probability distributions of the observed pathogenicity scores for all population variants and defined
disease-causing mutations. (D) Probability distributions of the pathogenicity scores for all variants and disease-causing mutations within each macro-
haplogroup. (E) Proportion of samples carrying disease-causing mutations. (F) Percentage of mtDNA sequences harboring two of more disease-
causing mutations.
https://doi.org/10.1371/journal.pgen.1007126.g002
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had much lower CpG% than other two groups for disease-causing mutations (5.88%; L versus
M p-value = 0.00049 and L versus N p-value = 0.15) (S7 Fig and S6 Table). These findings add
further weight to the hypothesis that haplogroup-specific sequence context influences the
acquisition of mtDNA mutations.
The age of mtDNA sequences
We then estimated the age of the each mtDNA sequence based on the major haplogroup classi-
fication, using the Rho statistic[18]. Overall, variants with higher pathogenicity scores were
found on ‘younger’ (more recent) mtDNA sequences (Fig 5A and 5B, p-value< 2.2e-16, Wil-
coxon Rank test). Disease-causing mutations were also found on younger mtDNA sequences
(Fig 5A, p-value = 0.019, Wilcoxon Rank test). When we studied the same relationship after
removing the main pathogenic allele from each sequence in silico (Fig 5C and 5D), we did not
observe an association between the remaining sequence and the age of predicted age of the
sequence. This indicates that the association between disease-causing variants and the age of
the mitochondrial genome is driven by the pathogenic variant itself and not the entire mtDNA
sequence. Although it is possible that Rho dating may be inaccurate in the absence of popula-
tion expansions [19], these observations are in keeping with the effects of natural section acting
on specific pathogenic variants.
The pathogenicity of mtDNA tRNAs
Finally, we estimated the pathogenicity scores for 207 variants in tRNA genes [20, 21]. Sev-
enty-four tRNA variants were present in 30,506 sequences, including 16 previously defined
disease-causing mutations (S4 Table). Consistent with the pathogenicity scores for non-
synonymous variants, all tRNA variants and disease-causing tRNA mutations with a higher
pathogenicity score were less frequent in the population (Fig 6A). Likewise, the probability
distributions for disease-causing tRNA mutations was significantly greater than the overall dis-
tribution of pathogenicity scores in the entire population (mean = 0.427 for disease-causing
tRNA mutations, mean = 0.102 for all possible tRNA variants; p-value< 2.2e-16, two-sample t
test; Fig 6A). Again, we observed that disease-causing tRNA mutations on macro-haplogroups
N and M had significantly higher pathogenicity score than those occurring on macro-hap-
logroup L (mean = 0.36 for L group, mean = 0.51 for M group, mean = 0.43 for N group; L ver-
sus M: p-value = 0.010, L versus N: p-value = 0.005, M versus N: p-value = 0.079, two- sample t
test; Fig 6B). However, there was no correlation between either all tRNA variants or disease-
causing tRNA mutations with the ages of the mtDNA sequences (Fig 6C and 6D). This could
reflect the limited number of tRNA variants in the data set, or that the effects of selection can-
not be detected for homoplasmic tRNA gene variants. This is in keeping with animal data,
where there is severe selection against protein coding variants within one or two generations,
but not tRNA variants[22].
Discussion
Our analysis of 30,506 human mtDNA sequences shows that the association between disease-
causing mtDNA mutations and background mtDNA haplogroups is not only restricted to
three disease-causing mtDNA mutations known to cause LHON. The frequent recurrence of
Fig 3. Frequency of disease causing mtDNA mutations in each macro-haplogroup. (A) Frequency of 13 disease causing
mutations present at >0.1% frequency in each haplogroup. (B) Disease-causing mutations significantly associated with specific mtDNA
haplogroups. Uncorrected p-value thresholds are shown.
https://doi.org/10.1371/journal.pgen.1007126.g003
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Fig 4. The mutational signatures observed in 30,506 mtDNA sequences. Each signature is displayed according to the 96 substitution
classification defined by the substitution class and sequence context immediately 3’ and 5’ to the mutated base. The probability bars for
the six types of substitutions are displayed in different colors and labeled at the top of the graph. The mutation types are on the horizontal
axes at the bottom of the graph. (A) All possible variants in macro-haplogroup L. (B) All possible variants in macro-haplogroup M. (C) All
possible variants in macro-haplogroup N. (D) All diseases-causing mutations in macro-haplogroup L. (E) All diseases-causing mutations
in macro-haplogroup M. (F) All diseases-causing mutations in macro-haplogroup N. The arrows highlight the variants in CpG
dinucleotides.
https://doi.org/10.1371/journal.pgen.1007126.g004
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the same mutations on a population clade, and the reduced frequency of European mtDNAs
harboring two or more diseases-causing mutation, both suggest that the population mtDNA
background influences the risk of developing mtDNA mutagenesis. Although it is conceivable
that this is due to the functional consequences of haplogroup variants, perhaps though the gen-
eration of increased oxygen free radicals, or the segregation of heteroplasmic variants, our
analysis indicates that this is unlikely because we also saw an association of mutations with
underlying sequence characteristics (such as CpG%) that are not directly linked to oxidative
phosphorylation or heteroplasmy segregation.
Our analysis also shows that disease-causing mtDNA mutations also occur more frequently
on younger mtDNAs. This implies that, once formed, the mutations are selected against.
Although tempting to think that this pattern simply reflects an ascertainment bias related to
the number of defined disease-causing mtDNA mutations in populations of European origin,
the data suggests that this is not the case. Firstly, the majority of mtDNA mutations were not
restricted to specific continental populations; and secondly a greater proportion of known dis-
ease-causing mutations were seen in the sequences derived from the Asian population (Fig 3
and S5 Fig). To our mind, the simplest explanation is that the more severe homoplasmic
mutations have been removed from the older populations through natural selection. A similar
pattern has been noted previously in older African mtDNA sequences[23], which have been
exposed to the effects of purifying selection for a longer period of time. This further endorses
the validity of our dataset and analysis. Thus, both a predilection to mutate and natural selec-
tion explain the associations between different mtDNA haplogroups and known-pathogenic
Fig 5. Predicted age of each mtDNA sequence. Age calculations are based on the Rho. (A) Distribution of
the mean pathogenicity scores of each mtDNA sequence and predicted age (Rho). Orange “x”: mtDNA
sequence not carrying disease-causing mutations; Purple “x”: mtDNA sequence carrying disease-causing
mutations. (B) Distribution of mean pathogenicity scores of each mtDNA sequence and predicted age (Rho)
(C) Distribution of mtDNA sequences with disease-causing mutations according to predicted age (Rho). (D)
Distribution of mtDNA sequences with non-disease-causing mutations according to predicted age (Rho).
https://doi.org/10.1371/journal.pgen.1007126.g005
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mutations, thereby explaining why different ethnic groups are more or less likely to present
with a specific mtDNA disease. However, it is important to note that other population genetic
effects could have influenced the current mtDNA landscape. For example, recent ancient
mtDNA studies point to a European population bottleneck ~14,500 years ago[24], which
could also explain the relative lack of evidence of selection in extant Europeans.
Our study was restricted to the major alleles within each mtDNA sequence, and not
designed to study the effects of mtDNA heteroplasmy. The prospective analysis of mtDNA het-
eroplasmy and the segregation of heteroplasmic variants in the population adds a further com-
plexity, but might cast further light on the mechanisms we propose. However, we did observe
common heteroplasmic mtDNAs within the dataset across all populations (eg. m.3243A>G),
and these variants followed the same overall patterns described here. In addition, no pheno-
typic data was available. Although a limitation, even without this information we can draw
some conclusions. First, despite the well-established strong association between LHON fami-
lies harboring m.3460G>A, m.11778G>A and m.14484T>C and mtDNA haplgroup J, at the
population level, these variants are found across a broad range of mtDNA haplogroups in all
three continental groups (Fig 3). In this study, m.14484T>C was found on multiple hap-
logroups, with an allele frequency up to 1.5% on haplogroup M(G). This contrasts sharply with
the almost exclusive association of m.14484T>C with haplogroup J described in epidemiologi-
cal studies of LHON[3, 4]. This strongly supports the view that haplogroup J modifies the
Fig 6. Pathogenicity of mtDNA tRNA variants in 30,506 mtDNA sequences. (A) Probability distributions
of the observed pathogenicity scores for all tRNA variants and defined disease-causing tRNA mutations. (B)
Probability distributions of the pathogenicity scores for all tRNA variants and disease-causing tRNA mutations
within each macro-haplogroup. (C) Distribution of the mean pathogenicity scores for tRNA variants of each
mtDNA sequence and predicted age (Rho). Orange “x”: mtDNA sequence not carrying disease-causing tRNA
mutations; Purple “x”: mtDNA sequence carrying disease-causing tRNA mutations. (D) Distribution of mean
pathogenicity scores for tRNA variants of each mtDNA sequence and predicted age (Rho) within each
macrohaplogroup.
https://doi.org/10.1371/journal.pgen.1007126.g006
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clinical penetrance of the m.3460G>A, m.11778G>A, and m.14484T>C mutations, and that
the association is not due to an increased mutation rate. Although we cannot be certain, this
indicates that the mutation has a reduced penetrance in certain contexts, perhaps related to
the nuclear genetic background or environmental factors. Whichever is the case, our findings
indicate that the clinical interpretation of mtDNA variants should be performed within an eth-
nogeographic context.
Materials and methods
mtDNA sequence source
30,619 human mtDNA sequences sampled from across the globe downloaded from GenBank
(https://www.ncbi.nlm.nih.gov/genbank/). 113 were removed due to poor sequence quality.
30,506 sequences were included in this study and aligned to Revised Cambridge Reference
Sequence (rCRS)[13] and Reconstructed Sapiens Reference Sequence (RSRS)[14] using
BLASTn (S1 Table).
Phylogenetic analysis
Haplogroup assignment was performed using HaploGrep 2[7]. Sequences were classified into
macro-haplogroups (L, M and N), major and sub-haplogroups based on the mtDNA phyloge-
netic tree[6] (http://www.phylotree.org/tree/index.htm) (S2 Table), including 3,852, 6,202
samples and 20,452 samples, respectively. Coalescence times were estimated using the ρ statis-
tic (average distance of the haplotypes of a clade from the respective root haplotype) accompa-
nied by a heuristic estimate of the standard error (σ) calculated from an estimate of the
genealogy[18].
Sequence quality control datasets
‘Sub-haplogroup tagged’ mtDNA sequences in GenBank database. We selected the
‘sub-haplogroup tagged’ mtDNA sequences it was possible to identify all known appropriate
haplogroup markers down to the sub-haplogroup level [6, 7] (http://www.phylotree.org/tree/
index.htm), including 1,142 sequences from macro-haplogroups L, 3,583 from M and 13,090
from N(S1 Table). Next we compared the frequencies of the variants to the remaining 12,691
sequences (non- sub-haplogroup tagged), stratifying for each macro-haplogroup (2,710
sequences from L, 2,619 from M and 7,362 from N; S1 Table). The allele frequency (AF) differ-
ence of each variant between two groups was calculated as log2 (ratio of frequencies from two
groups).
mtDNA sequences in 1000 genome project. mtDNA sequences from 2,182 samples were
downloaded from 1000 Genome Project (http://www.internationalgenome.org/). mtDNA
haplogroup of each sequence was predicted using HaploGrep 2[7] and mt-classifier[21]. We
excluded the low quality mtDNA sequences using the following criteria: 1) when <90% of the
known haplogroup markers were present for each mtDNA sequence; 2) when more than one
haplogroup prediction was reported; 3) when the haplogroups predicted by two prediction
tools were inconsistent. There were 1,370 mtDNA sequences, including 462 sequences from
macro-haplogroups L, 271 from M and 637 from N for the further QC analysis.
Other published mtDNA sequences. We compared the ratio of non-synonymous to syn-
onymous substitutions of 3,852 mtDNA sequences in macro-haplogroup L, 6,202 in M and
2,662 in N (nonR) from this study to 1,125 published global human mtDNA sequences (445
mtDNA sequences in macro-haplogroup L, 239 in M and 199 in N (nonR))[9], across the
entire mtDNA phylogenetic tree. For the 17,790 European haplogroup N(R) sequences we also
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compared the frequency of 59 mtDNA variants to 9,935 population controls from the Well-
come Trust Case Control Consortium[8].
Determining the disease caused mutations
We determined which variants were likely to be pathogenic. We listed the variants which were
present in 30,506 mtDNA sequences and also proposed pathogenic mtDNA variants on the
ClinVar database[11]. We did not include data where two or more nucleotide variations and
Indels were listed (S4 Table). We then reviewed published and on-line evidence of pathogenic-
ity for each one of the 90 variants using the following criteria: (1) Reported more than once
with mtDNA disease and/or (2) Documented heteroplasmy, with evidence of segregation with
the phenotype at the clinical or biochemical level.
Pathogenicity measure
The MutPred analysis score[25] was used for the pathogenicity of an amino acid variation for
the 13 proteins encoded by the mtDNA. Pathogenicity scores were calculated for all of the
24,206 possible amino acid variations defined by a single point mutation away from the refer-
ence sequence (S7 Table). The list of all possible amino acid variations from the reference
sequence (rCRS)[13] was defined by using the mtDNA-GenesSyn software[26]. The pathoge-
nicity scores of variants in tRNA genes were retrieved from the literature[20, 21].
The MutPred score is determined by a set of features reflecting protein structure and its
dynamics, the presence of functional residues, biases of amino acid sequence, and evolutionary
conservation at the substitution site and in its neighborhood. The software was trained as a
random forest classification model to discriminate between disease-associated amino acid sub-
stitutions from the Human Gene Mutation Database and putatively neutral polymorphisms
from Swiss-Prot, and is thus not directly dependent on allele frequencies in the human
population.
Mutational signature
Mutational spectra were derived directly from the both rCRS [13] and RSRS mtDNA[14] ref-
erence sequences and alternative alleles at each variant site. The resulting spectra are composed
of the relative frequencies of the six distinguishable point mutations (C:G>T:A, T:A>C:G, C:
G>A:T, C:G>G:C, T:A>A:T and T:A>G:T). Each signature was displayed using a 96 substi-
tution classification defined by the substitution class and the sequence context immediately 3’
and 5’ to the mutated base[12].
Statistical analysis
The p-values for all comparisons of mean values were calculated by using two-sample t tests or
Wilcoxon Rank test as appropriate. Variant counts or fractions were performed using Fisher’s
exact test. Pearson’s correlation coefficient (R2) and the significance were calculated using the
correlation test. All statistical analyses were performed using R (v3.3) (https://www.r-project.
org).
Data availability
The mtDNA sequences that support the findings of this study are available in Genbank:
https://www.ncbi.nlm.nih.gov/genbank/. Accession numbers are supplied in S1 Table. No
other data is generated specifically in this study.
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Supporting information
S1 Fig. Correlation of allele frequency (AFs) of the variants between 17,815 sub-haplogroup
tagged mtDNA sequences and 12,691 non sub-haplogroup tagged sequences in NCBI data-
base. (a) The allele frequencies of variants in 12,691 non sub-haplogroup tagged sequences were
highly correlated with 17,815 sub-haplogroup tagged sequences within each marco-haplogroup.
AFs were shown in log2(AF/1-AF). (b)There was no relationship between the AF difference of
sub-haplogroup tagged sequences(AF_tagged) and non sub-haplogroup tagged sequences
(AF_non-tagged) with the pathogenic scores of variants in each macro-haplogroup.
(EPS)
S2 Fig. Correlation of allele frequency (AFs) of the variants between 1000 Genome Project
and 30,506 NCBI mtDNA sequences, AFs were shown in log2(AF/1-AF). The allele frequen-
cies of variants in 1000 Genome Project were highly correlated with 30,506 NCBI mtDNA
sequences within each marco-haplogroup. L, M and N groups were shown, respectively.
(EPS)
S3 Fig. Correlation of allele frequencies (AFs) of non haplogroup makers between 1000
Genome Project and 30,506 NCBI mtDNA sequences, AFs were shown in log2(AF/1-AF).
Macro-haplogroup L, M and N were shown in different colors, respectively.
(EPS)
S4 Fig. Correlation of pathogenicity score between polymorphisms and disease-causing
mutations. (a) The correlation of mean pathogenicity score between all variants of each
mtDNA sequence and only disease-causing mutations of each mtDNA sequence. (b) The cor-
relation of mean pathogenicity score between non-disease-causing mutations of each mtDNA
sequence and only disease-causing mutations of each mtDNA sequence.
(EPS)
S5 Fig. Comparison of the presence of specific disease causing mtDNA mutations in each
macro-haplogroup. Columns left to right: mtDNA variant; mutations specific to macro-hap-
logroup L (blue); mutations specific to macro-haplogroup M (pink); mutations specific to
macro-haplogroup N (green); mutations found on all three macro-haplogroups L,M&N (pur-
ple); mutations found on more than one macro-haplogroup (yellow); mutations found on one
macro-haplogroup (violet). No = number of variants found in each category.
(EPS)
S6 Fig. The categories of mutational signatures observed in 30,506 mtDNA sequences.
30,506 mtDNA sequences were realigned against Reconstructed Sapiens Reference Sequence
(RSRS). The probability bars for the six types of substitutions (C>A, C>G, C>T, T>A, T>C
and T>G) are displayed within each macro-haplogroup.
(EPS)
S7 Fig. Comparison of the distribution of CpG% (%C>T) in macro-haplogroups. (a) Dis-
tribution of CpG% (%C>T) in all possible variants. (b) distribution of CpG% (%C>T) in dis-
ease-causing mutations.
(EPS)
S1 Table. The mtDNA sequences IDs and haplogroup of each sequence used in this study.
17,815 of the 30,506 mtDNA sequences which was possible to identify all known appropriate
haplogroup markers down to the sub-haplogroup level were labeled as sub-haplogroup tagged
in the QC column.
(XLSX)
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S2 Table. Sample size of each haplogroup and macro-haplogroup.
(DOCX)
S3 Table. The details of 202 reported pathogenic variations in ClinVar.
(XLSX)
S4 Table. The details of 57 defined disease-causing mutations in 30,506 mtDNA sequences.
(XLSX)
S5 Table. Comparison of the CpG% between all possible variants and disease-causing
mutations for the entire population and each group. The percentage of variants in CpG
region and the p-value for Fisher’s exact test—all possible variants vs all disease-causing muta-
tions in the entire population and each group were shown and calculated.
(DOCX)
S6 Table. Comparison of the CpG% between any two of three groups. The p-value for Fish-
er’s exact test—each group vs the rest of groups were shown and calculated.
(DOCX)
S7 Table. The Pathogenicity scores of all possible protein variants.
(XLSX)
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